NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS
Post# of 98
(Total Views: 58)
Posted On: 08/15/2024 4:13:19 PM
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from its Phase 3 PD study revealed that buntanetap led to improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. The company also discussed the filing of patents, team updates, and other achievements.
“The recent months have been productive for our company,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio. “We’ve completed pivotal Phase 2/3 Alzheimer’s and Phase 3 Parkinson’s studies, both of which revealed very encouraging data for buntanetap. Additionally, we’ve introduced a new crystalline form of buntanetap with improved properties, further strengthening our IP portfolio. These milestones position us strongly as we move closer to providing much-needed treatments to patients.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from its Phase 3 PD study revealed that buntanetap led to improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. The company also discussed the filing of patents, team updates, and other achievements.
“The recent months have been productive for our company,” said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio. “We’ve completed pivotal Phase 2/3 Alzheimer’s and Phase 3 Parkinson’s studies, both of which revealed very encouraging data for buntanetap. Additionally, we’ve introduced a new crystalline form of buntanetap with improved properties, further strengthening our IP portfolio. These milestones position us strongly as we move closer to providing much-needed treatments to patients.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼